Multiple Myeloma Treatment Trends

Multiple myeloma is complex, and continuous therapy has been shown to improve outcomes.1-3


Continuous therapy doubled median PFS vs fixed-duration therapy3
Results from Palumbo et al pooled analysis of three phase 3 studies*

Chart showing that continuous therapy doubled median PFS vs fixed-duration therapy. PFS was 16 months with fixed-duration therapy, and 32 months with continuous therapy. Results from Palumbo et al pooled analysis of three phase 3 studies.
Adapted from Palumbo et al, 2015.3 
*Patients received ASCT and/or immunomodulatory drugs in various combinations with proteasome inhibitors, chemotherapy, or CSTs.4 
ASCT=autologous stem-cell transplantation; CI=confidence interval; CST=corticosteroid therapy; CT=continuous treatment; FDT=fixed-duration treatment: HR=hazard ratio; PFS=progression-free survival.

Proteasome inhibition remains a cornerstone of multiple myeloma treatment with optimal outcomes1,5

  • Proteasome inhibition has been a standard of care in the treatment of multiple myeloma for >15 years
  • Triplet regimens, including those containing a PI, have demonstrated superior efficacy vs doublet regimens1,2

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend triplet regimens for patients with multiple myeloma2

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Treatment with injectable PIs can be difficult to continue because of6:


Adverse Reactions7,8


Burden of Repeated IV or SQ Administration Impacting Patients' HRQOL9


Restricted Mobility9


Desire to Remain Outside of a Hospital or Clinic9

HRQOL=health-related quality of life; IV=intravenous; SC=subcutaneous.

NINLARO patient profiles

Different patient types with relapsed multiple myeloma may benefit from the NINLARO triplet regimen.

NINLARO clinical trial data

The TOURMALINE-MM1 trial evaluated efficacy and safety of the all-oral NINLARO regimen vs Rd regimen in relapsed patients with multiple myeloma.